Sponsor: AbbVie, Inc
Sponsor Study ID: M24-427
Study Title: A Phase 1 Open Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications
CTO #: 103955
NCT Number: NCT06084481
Phase: I
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Anus, Bladder, Cervix Uteri, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, Skin, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid
Study Objectives: To assess the efficacy of ABBV-400 in each solid tumor indication, including advanced or metastatic HCC, BTC, PDAC, ESCC, TNBC, HR+/HER2- BC and HNSCC. To characterize the safety and tolerability of ABBV-400 as monotherapy in advanced or metastatic HCC, BTC, PDAC, ESCC, TNBC, HR+/HER2- BC, and HNSCC.